Merck: SILu™MAb Infliximab

SILu™MAb Infliximab(MSQC9) is a recombinant, stable isotope-labeled, monoclonal antibody which incorporates [13C6, 15N4]-Arginine and [13C6, 15N2]-Lysine. Expressed in CHO cells, it is designed to be used as an internal standard for the quantitative mass spectrometry analysis of Infliximab in human serum. Infliximab is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases. Infliximab has been approved for the treatment of Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. SILu™MAb Infliximab is for research use only and is not intended for diagnostic or therapeutic use.

Application note for SILu™MAb Infliximab

Quantification of Infliximab in Human Serum by LC-MS/MS

For more information, visit sigma-aldrich.com/silumab